Treatment for dupuytren's disease
First Claim
Patent Images
1. A method for treating a patient with early disease state adhesive capsulitis comprising injecting an amount of a TNF-α
- antagonist effective to treat the patient directly into one or more clinical or histological nodules at the site of the early disease state adhesive capsulitis, so as to treat the patient.
2 Assignments
0 Petitions
Accused Products
Abstract
Musculoskeletal fibroproliferative disorders, such as Dupuytren'"'"'s disease may be treated by administering locally a TNF-α antagonist. TNF-α antagonists find particular utility in inhibiting the progression of early disease state Dupuytren'"'"'s disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such as collagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren'"'"'s disease and, in particular inhibiting recurrence.
-
Citations
11 Claims
-
1. A method for treating a patient with early disease state adhesive capsulitis comprising injecting an amount of a TNF-α
- antagonist effective to treat the patient directly into one or more clinical or histological nodules at the site of the early disease state adhesive capsulitis, so as to treat the patient.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
Specification